Institutional members access full text with Ovid®

Share this article on:

Transient Myeloproliferative Disorder in a Newborn With Down Syndrome

Rhoderick, Janelle Ann RNC, MSN1; Bradshaw, Wanda Todd RNC, MSN2

Section Editor(s): KING, CHERYL MS, CCRN

doi: 10.1097/01.ANC.0000333708.45399.8f
Case of the Month

This is the report of a newborn with Down syndrome diagnosed with transient myeloproliferative disorder (TMD) that required chemotherapy on the first day of life. Children with Down syndrome have a 10- to 20-fold increased risk of developing TMD. TMD is characterized by an uncontrolled proliferation of myeloblasts in the infant's peripheral blood and bone marrow. In most instances, this unique disorder has the ability to spontaneously “turn off” the overproliferation and enter a state of remission. Only supportive care is recommended for TMD during the first months of life unless the clinical condition requires intervention. As more cases of this baffling disorder are presented, it is important to share our experience to aid in management and diagnosis.

1National Naval Medical Center Bethesda, Maryland, and 2Duke University School of Nursing, Intensive Care Nursery, Duke University Hospital, Durham, North Carolina.

Address correspondence to Janelle Ann Rhoderick, RNC, MSN, 18007 Foxworth Court, Germantown, MD 20874; janelle.rhoderick@med.navy.mil

The authors have no significant ties, financial or otherwise, to any company that might have an interest in the publication of this educational activity.

© 2008 National Association of Neonatal Nurses